<DOC>
	<DOCNO>NCT00014456</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Colony-stimulating factor filgrastim may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . PURPOSE : Phase I trial study effectiveness combination chemotherapy plus filgrastim treating patient advance solid tumor .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Filgrastim Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose docetaxel combination gemcitabine filgrastim ( G-CSF ) patient advance solid tumor . - Determine dose-limiting toxicity associate regimen patient . - Assess objective anti-tumor response patient treat regimen . - Determine fatigue blood cytokine patient treat regimen . OUTLINE : This dose-escalation study docetaxel . Patients receive docetaxel IV 1 hour follow gemcitabine IV 30 minute day 1 . Patients also receive filgrastim ( G-CSF ) subcutaneously daily begin day 2 continue blood count recover . Treatment repeat every 14 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos docetaxel maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Fatigue assess baseline week 2 , 5 , 7 , 9 therapy . PROJECTED ACCRUAL : A maximum 30 patient accrue study within 15-22 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Unknown Primary</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm advanced solid tumor curable surgery radiotherapy Sarcoma Melanoma Carcinoma unknown primary Pancreatic cancer Lung cancer Ovarian cancer Breast cancer Bladder cancer Gastric cancer Esophageal cancer Prostate cancer Head neck cancer No hematopoietic lymphoid tumor Measurable evaluable disease PATIENT CHARACTERISTICS : Age : Over 18 Performance status : Karnofsky 60100 % ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 1,000/mm^3 Platelet count great 100,000/mm^3 Hepatic : Bilirubin normal AST and/or ALT great 5 time upper limit normal ( ULN ) alkaline phosphatase great ULN OR Alkaline phosphatase great 5 time ULN AST ALT great ULN OR AST and/or ALT great 1.5 time ULN alkaline phosphatase great 2.5 time ULN Renal : Creatinine great 2 time ULN OR Creatinine clearance least 50 mL/min Cardiovascular : No congestive heart failure No unstable angina Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled infection No known sensitivity E. coliderived product PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 2 week since prior cytotoxic antitumor therapy ( 4 week nitrosourea mitomycin ) recover No prior docetaxel gemcitabine Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 2 week since prior radiotherapy recover Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>metastatic osteosarcoma</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>chondrosarcoma</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>recurrent osteosarcoma</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>stage IV salivary gland cancer</keyword>
	<keyword>recurrent salivary gland cancer</keyword>
	<keyword>classic Kaposi sarcoma</keyword>
	<keyword>AIDS-related Kaposi sarcoma</keyword>
	<keyword>recurrent Kaposi sarcoma</keyword>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>stage IV ovarian germ cell tumor</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>stage IV uterine sarcoma</keyword>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>borderline ovarian surface epithelial-stromal tumor</keyword>
	<keyword>recurrent carcinoma unknown primary</keyword>
	<keyword>ovarian sarcoma</keyword>
	<keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>recurrent verrucous carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage IV verrucous carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent lymphoepithelioma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV lymphoepithelioma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent lymphoepithelioma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV lymphoepithelioma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent verrucous carcinoma oral cavity</keyword>
	<keyword>stage IV verrucous carcinoma oral cavity</keyword>
	<keyword>recurrent basal cell carcinoma lip</keyword>
	<keyword>stage IV basal cell carcinoma lip</keyword>
	<keyword>recurrent mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>stage IV mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>recurrent adenoid cystic carcinoma oral cavity</keyword>
	<keyword>stage IV adenoid cystic carcinoma oral cavity</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>